At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 69 enrolled
Drug / intervention
CP-690,550 (tasocitinib)drug
Likely dose
CP-690,550 (tasocitinib) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis
In Brief
A Phase 1 clinical trial evaluating CP-690,550 (tasocitinib) for Rheumatoid Arthritis. Completed, enrolled 69 participants across 11 sites in 2 countries.
Detailed Summary
The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesHungary, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartMay 2011
Primary CompletionJan 2012
Study CompletionFeb 2012
TodayJul 2026
First PostedDec 17, 2010
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2012
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.5 years ago
Interventions
CP-690,550 (tasocitinib)drug
CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis